Benitec Biopharma Inc. reported no revenues for the quarter ended September 30, 2025, consistent with the same period in 2024. Total operating expenses rose to $9.8 million from $5.8 million in the prior year quarter, primarily due to higher general and administrative costs, which increased to $6.4 million from $2.2 million, while research and development expenses decreased slightly to $3.4 million from $3.6 million. The net loss attributable to shareholders was $9.0 million, or $(0.22) per basic and diluted share, compared to $5.1 million, or $(0.18) per basic and diluted share in the previous year. Cash and cash equivalents stood at $94.5 million as of September 30, 2025. In November 2025, Benitec raised approximately $100 million through a public offering of common stock. The company also reported that the FDA granted Fast Track Designation for its BB-301 candidate in Oculopharyngeal Muscular Dystrophy, following positive interim clinical study results.